CAPLYTA offers two dosage strengths for Special Populations.1
Reduce dosing for1:
- Concomitant use with moderate CYP3A4 inhibitors (21 mg) or with strong CYP3A4 inhibitors (10.5 mg)
- Patients with moderate (Child-Pugh class B) or severe (Child-Pugh class C) hepatic impairment (21 mg)
Avoid concomitant use with CYP3A4 inducers.
Increased monitoring for SRI-associated adverse reactions is recommended when used with SRIs; including in geriatric patients who may be at greater risk for clinically significant hyponatremia.
- Although no clinically significant drug interactions with adjunctive SSRI/SNRIs in MDD were observed in CAPLYTA clinical trials, CAPLYTA's moderate serotonin transporter (SERT) activity may increase the risk of SRI-associated adverse reactions (e.g., serotonin syndrome, hyponatremia)
aMDD=adjunctive major depressive disorder; SNRI=serotonin and norepinephrine reuptake inhibitor; SRI=serotonin reuptake inhibitor; SSRI=selective serotonin reuptake inhibitor.
